Medicenna in the spotlight

Deep-dive on company fundamentals and early-stage IL-2 asset landscape

Medicenna (MDNA) is developing a next-gen IL-2 candidate against solid tumors. The company expects to report Phase 1 biomarker data by the end of 2021, which could be the first step in replicating its promising preclinical data in humans. Big pharma and sophisticated biotech funds have thrown billions of dollars to gain access to preclinical and early P…